Gain Therapeutics Inc
NASDAQ:GANX
Intrinsic Value
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. [ Read More ]
The intrinsic value of one GANX stock under the Base Case scenario is 0.07 USD. Compared to the current market price of 3.03 USD, Gain Therapeutics Inc is Overvalued by 98%.
Valuation Backtest
Gain Therapeutics Inc
Run backtest to discover the historical profit from buying and selling GANX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Gain Therapeutics Inc
Current Assets | 17.8m |
Cash & Short-Term Investments | 16.8m |
Receivables | 242.6k |
Other Current Assets | 741.6k |
Non-Current Assets | 830.5k |
PP&E | 778.6k |
Other Non-Current Assets | 51.9k |
Current Liabilities | 4.9m |
Accounts Payable | 1.3m |
Accrued Liabilities | 2m |
Other Current Liabilities | 1.7m |
Non-Current Liabilities | 1.1m |
Long-Term Debt | 449.1k |
Other Non-Current Liabilities | 632.1k |
Earnings Waterfall
Gain Therapeutics Inc
Revenue
|
55.2k
USD
|
Operating Expenses
|
-22.3m
USD
|
Operating Income
|
-22.3m
USD
|
Other Expenses
|
-14.4k
USD
|
Net Income
|
-22.3m
USD
|
Free Cash Flow Analysis
Gain Therapeutics Inc
GANX Profitability Score
Profitability Due Diligence
Gain Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Gain Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
GANX Solvency Score
Solvency Due Diligence
Gain Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Gain Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GANX Price Targets Summary
Gain Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GANX is 8.98 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.
Ownership
GANX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GANX Price
Gain Therapeutics Inc
Average Annual Return | -45.94% |
Standard Deviation of Annual Returns | 7.77% |
Max Drawdown | -87% |
Market Capitalization | 49.8m USD |
Shares Outstanding | 16 219 700 |
Percentage of Shares Shorted | 0.91% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2021-03-18. The Company, through its subsidiary, GT Gain Therapeutics SA, is a development stage biotechnology company. The firm is focused on developing therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. The company uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which are small molecules with the potential to treat diseases with unmet medical need. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.
Contact
IPO
Employees
Officers
The intrinsic value of one GANX stock under the Base Case scenario is 0.07 USD.
Compared to the current market price of 3.03 USD, Gain Therapeutics Inc is Overvalued by 98%.